1996•PubMedRequires access

Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis.

Larry W. Moreland

Abstract

The combination of traditional disease modifying antirheumatic drugs such as methotrexate (MTX) with biologic agents for treating rheumatoid arthritis (RA) has thus far been limited. The combination of MTX and a depleting anti-CD4 monoclonal antibody (cM-T412) has been evaluated in phase I and II trials in patients with refractory RA. The potential of combining MTX with other biologic agents is reviewed.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Medicine, Methotrexate, Rheumatoid arthritis, Antirheumatic drugs, Biologic Agents, Antirheumatic Agents, Monoclonal antibody, Refractory (planetary science)